A phase II study of gefitinib and fulvestrant in patients with advanced, EGFR mutated non-small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors.
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2015
At a glance
- Drugs Fulvestrant (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Oct 2015 Status changed from recruiting to completed,as reported by Netherlands Trial Register.
- 05 Jul 2012 New source identified and integrated (EudraCT2012-000345-12).
- 13 Jun 2012 Status changed from not yet recruiting to planning as reported by Netherlands Trial Register.